Johnson & Johnson 配当と自社株買い
配当金 基準チェック /56
Johnson & Johnsonは配当を支払う会社で、現在の利回りは2.09%ですが、利益によって十分にカバーされています。次の支払い日は 8th September, 2026で、権利落ち日は25th August, 2026 。
主要情報
2.1%
配当利回り
0.6%
バイバック利回り
| 総株主利回り | 2.7% |
| 将来の配当利回り | 2.2% |
| 配当成長 | 5.5% |
| 次回配当支払日 | 08 Sep 26 |
| 配当落ち日 | 25 Aug 26 |
| 一株当たり配当金 | n/a |
| 配当性向 | 60% |
最近の配当と自社株買いの更新
Recent updates
ナラティブ更新 • Jul 31
JNJ: New Drug Cycle And Talc Settlement Progress Will Balance Policy Risks
Johnson & Johnson's analyst fair value estimate has been raised from $252.87 to $270.59, reflecting higher Street price targets tied to recent Q2 beats, updated guidance, progress on new medicines, and greater clarity around talc litigation exposure. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of enthusiasm around execution on new medicines and MedTech, alongside measured caution on policy and competitive pressures.
ナラティブ更新 • Jul 17
JNJ: Oncology Focus And New Medicines Will Drive Confidence Through 2026
Analysts raised the Johnson & Johnson fair value estimate to $305 from $265 after a series of price target increases tied to a recent quarterly beat, higher full year guidance, and growing confidence in the company's new medicines and projected revenue trajectory through 2026. Analyst Commentary Recent Street research around Johnson & Johnson has turned more constructive, with a cluster of upgrades and higher price targets following the latest quarterly results and revised guidance.Seeking Alpha • Jul 15
Johnson & Johnson Q2: Solid (If Not Spectacular) Performance Satisfies Wall Street
Summary Johnson & Johnson delivered strong Q2 2026 results, with 6.6% annual revenue growth and robust performance across Pharma and MedTech divisions. JNJ maintains mid-to-high single digit revenue growth, a portfolio of 15+ "blockbuster" drugs, and a solid pipeline, supporting its blue-chip status. I am downgrading JNJ from Strong Buy to Buy due to valuation normalization and tempered forward share price expectations, despite continued operational strength. JNJ offers stable dividends (>2% yield), high profitability (27.5% operating margin in 2025), and remains a reliable 'buy and hold' within Big Pharma. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 03
JNJ: Drug Pipeline Optimism Will Face Pressure From Medicare Pricing Rules
For Johnson & Johnson, the analyst price target has been revised higher. The updated fair value estimate has moved from about $181.77 to $212.24 as analysts factor in refreshed revenue growth assumptions, slightly adjusted discount and margin inputs, and a higher future P/E in light of recent research pointing to ongoing new drug momentum and broadly supportive earnings expectations.分析記事 • Jun 21
Johnson & Johnson (JNJ) Stock Could Be 7.3% Undervalued Based On Its Pharma And MedTech Focus
Johnson & Johnson (JNJ) is back in focus after recent share price weakness, with the stock down 2% over the past month and about 3% over the past 3 months, prompting fresh interest in its valuation. See our latest analysis for Johnson & Johnson. Despite the recent share price weakness over the past week and quarter, Johnson & Johnson’s year to date share price return of 10.15% and 1 year total shareholder return of 56.28% point to momentum that has been positive overall. If this kind of move...ナラティブ更新 • Jun 19
JNJ: Future Drug Cycle And Dividend Strength Will Balance Policy And Legal Risks
Analysts have raised the Johnson & Johnson price target to $265 from $252, reflecting increased confidence in the company’s new drug momentum and product cycle, while also considering ongoing policy and partnership risks highlighted in recent research. Analyst Commentary Recent Street research around Johnson & Johnson highlights a mix of enthusiasm about the company’s new drug pipeline and product cycle, alongside fresh policy questions and selected partnership headwinds that investors should factor into expectations for execution and valuation.ナラティブ更新 • Jun 04
JNJ: Future Drug Cycle Momentum Is Expected To Drive Returns
Analysts have nudged their price targets for Johnson & Johnson higher, with recent revisions clustering in the mid to high $260s and up to $280, as they point to strong new drug momentum and product cycle strength as key drivers supporting slightly higher revenue growth expectations and a rich future P/E framework. Analyst Commentary Recent research remains broadly constructive on Johnson & Johnson, with several bullish analysts citing product cycle momentum, new drug contributions, and a supportive P/E setup.ナラティブ更新 • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.ナラティブ更新 • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.ナラティブ更新 • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.ナラティブ更新 • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.新しいナラティブ • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.ナラティブ更新 • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.ナラティブ更新 • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.ナラティブ更新 • Jan 27
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward
Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.配当金の支払いについて
決済の安定と成長
配当データの取得
安定した配当: JNJの1株当たり配当金は過去10年間安定しています。
増加する配当: JNJの配当金は過去10年間にわたって増加しています。
配当利回り対市場
| Johnson & Johnson 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (JNJ) | 2.1% |
| 市場下位25% (US) | 1.3% |
| 市場トップ25% (US) | 4.0% |
| 業界平均 (Pharmaceuticals) | 1.9% |
| アナリスト予想 (JNJ) (最長3年) | 2.2% |
注目すべき配当: JNJの配当金 ( 2.09% ) はUS市場の配当金支払者の下位 25% ( 1.32% ) よりも高くなっています。
高配当: JNJの配当金 ( 2.09% ) はUS市場の配当金支払者の上位 25% ( 4.05% ) と比較すると低いです。
株主への利益配当
収益カバレッジ: JNJの配当金は、合理的な 配当性向 ( 60% ) により、利益によって賄われています。
株主配当金
キャッシュフローカバレッジ: JNJは合理的な 現金配当性向 ( 59.1% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/31 03:51 |
| 終値 | 2026/07/31 00:00 |
| 収益 | 2026/06/28 |
| 年間収益 | 2025/12/28 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Johnson & Johnson 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。53
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |